45th week of 2013 patent applcation highlights part 50 |
Patent application number | Title | Published |
20130296179 | NUCLEIC ACID PROBE-BASED DIAGNOSTIC ASSAYS FOR PROKARYOTIC AND EUKARYOTIC ORGANISMS - Use of the ssrA gene or tmRNA, an RNA transcript of the ssrA gene, or fragments thereof as target regions in a nucleic acid probe assay for the detection and identification of prokaryotic and/or eukaryotic organisms is described. Nucleotide sequence alignment of tmRNA sequences from various organisms can be used to identify regions of homology and non-homology within the sequences which in turn can be used to design both genus specific and species specific oligonucleotide probes. These newly identified regions of homology and non-homology provide the basis of identifying and detecting organisms at the molecular level. Oligonucleotide probes identified in this way can be used to detect tmRNA in samples thereby giving an indication of the viability of non-viral organisms present in various sample types. | 2013-11-07 |
20130296180 | PROCESSES AND COMPOSITIONS FOR METHYLATION-BASED ENRICHMENT OF FETAL NUCLEIC ACID FROM A MATERNAL SAMPLE USEFUL FOR NON-INVASIVE PRENATAL DIAGNOSES - Provided are compositions and processes that utilize genomic regions differentially methylated between a mother and her fetus to separate, isolate or enrich fetal nucleic acid from a maternal sample. The compositions and processes described herein are useful for non-invasive prenatal diagnostics, including the detection of chromosomal aneuploidies. | 2013-11-07 |
20130296181 | COMPOSITIONS AND ASSAYS TO DETECT SWINE H1N1 INFLUENZA A VIRUS, SEASONAL H1 INFLUENZA A VIRUS AND SEASONAL H3 INFLUENZA A VIRUS NUCLEIC ACIDS - Methods for detecting the presence or absence of the swine H1N1 influenza A virus, seasonal H1 influenza A virus and/or seasonal H3 influenza A virus nucleic acids in biological samples are disclosed. Compositions that are target-specific nucleic acid sequences and kits comprising target-specific nucleic acid oligomers for amplifying in vitro the swine H1N1 influenza A virus, seasonal H1 influenza A virus and/or seasonal H3 influenza A virus nucleic acid and detecting amplified nucleic acid sequences are disclosed. | 2013-11-07 |
20130296182 | VARIABILITY SINGLE NUCLEOTIDE POLYMORPHISMS LINKING STOCHASTIC EPIGENETIC VARIATION AND COMMON DISEASE - Provided are methods and models for an alternative source of disease risk, which identifies not genetic variants for a phenotype per se, but variants for variability itself. Also provided are methods and models for a genome-scale, gene-specific analysis of DNA methylation in the same individuals over time, in order to identify a personalized epigenomic signature that may correlate with common genetic disease. Also provided are methods and models for simulating stochastic epigenetic variation as a driving force of development, evolutionary adaptation, and disease. | 2013-11-07 |
20130296183 | FUNCTIONAL GENOMICS ASSAY FOR CHARACTERIZING PLURIPOTENT STEM CELL UTILITY AND SAFETY - The present invention generally relates set of reference data or “scorecard” for a pluripotent stem cell, and methods, systems and kits to generate a scorecard for predicting the functionality and suitability of a pluripotent stem cell line for a desired use. In some aspects, a method for generating a scorecard comprises using at least 2 stem cell assays selected from: epigenetic profiling, differentiation assay and gene expression assay to predict the functionality and suitability of a pluripotent stem cell line for a desired use. In some embodiments, the scorecard reference data can be compared with the pluripotent stem cells data to effectively and accurately predict the utility of the pluripotent stem cell for a given application, as well as any to identify specific characteristics of the pluripotent stem cell line to determine their suitability for downstream applications, such as for example, their suitability for therapeutic use, drug screening and toxicity assays, differentiation into a desired cell lineage, and the like. | 2013-11-07 |
20130296184 | Novel Method for Diagnosing Lyme Disease Using a Cellular Immunological Test - The present invention relates to a method for diagnosing Lyme disease in a subject, the method comprising the steps of: (a) obtaining a sample from said subject, (b) contacting said sample with a source of | 2013-11-07 |
20130296185 | TAPE STRIPPING METHODS FOR ANALYSIS OF SKIN DISEASE AND PATHOLOGICAL SKIN STATE - The present invention provides non-invasive methods for detecting, monitoring, and diagnosing skin disease and pathological skin states such as irritated skin and psoriasis. The methods include using tape stripping to analyze expression in epidermal samples, of one or more skin markers. In illustrative examples, the tape stripping is performed using pliable tape that has a rubber adhesive. Furthermore, the present invention provides methods for predicting and monitoring response to therapy for a skin disease, such as psoriasis or dermatitis. Finally, the methods can include the use of a microarray. | 2013-11-07 |
20130296186 | SELF-ENCODING SENSOR WITH MICROSPHERES - Disclosed herein are compositions and methods for combining the output obtained from redundant sensor elements in a sensor array. | 2013-11-07 |
20130296187 | Microfluidics System for Sequencing - A sensor chip ( | 2013-11-07 |
20130296188 | TARGETING METABOLIC ENZYMES IN HUMAN CANCER - Targeting metabolic enzymes in human cancer Abstract Lung cancer is a devastating disease and a major therapeutic burden with poor prognosis. The functional heterogeneity of lung cancer (different tumor formation ability in bulk of tumor) is highly related with clinical chemoresistance and relapse. Here we find that, glycine dehydrogenase (GLDC), one of the metabolic enzyme involved in glycine metabolism, is overexpressed in various subtypes of human lung cancer and possibly several other types of cancers. GLDC was found to be highly expressed in tumor-initiating subpopulation of human lung cancer cells compared with non-tumorigenic subpopulation. By array studies we showed that normal lung cells express low levels of GLDC compared to xenograft and primary tumor. Functional studies showed that RNAi inhibition of GLDC inhibits significantly the clonal growth of tumor-initiating cells in vitro and tumor formation in immunodeficient mice. Overexpression of GLDC in non-tumorigenic subpopulation convert the cells to become tumorigenic. Furthermore, over-expression of GLDC in NIH/3T3 cells and human primary lung fibroblasts can transform these cells, displaying anchorage-independent growth in soft agar and tumor-forming in mice. Not only is GLDC is expressed human lung cancer, it is also up-regulated in other types of cancer, such as colon cancer. RNAi knockdown of GLDC in colon cancer cell line, CACO-2 cells, can also inhibit the tumor formation in mice. Thus GLDC maybe a new metabolic target for treatment of lung cancer, and other cancers. | 2013-11-07 |
20130296189 | PROBES UTILIZING UNIVERSAL TAGS, A KIT COMPRISING THE SAME AND DETECTION METHODS - The present invention provides a kit and a detection method for multiple targets detection of biomolecules. The kit comprises a universal tag, a probe and an optional instruction for using the same. The universal tag in the present invention is a fragment of DNA, RNA, peptide nucleic acid, or LNA, and is 3-20 mer in length. The probe in the present invention contains in order from 3′ terminus to 5′ terminus, a nucleotide sequence which is reverse complementary to a target molecule or a portion of the target molecule, and a nucleotide sequence which is reverse complementary to the universal tag; or said probe contains in order from 3′ terminus to 5′ terminus, a nucleotide sequence which is reverse complementary to the universal tag, and a nucleotide sequence which is reverse complementary to a target molecule or a portion of the target molecule. | 2013-11-07 |
20130296190 | PREDICTION OF SPONTANEOUS PRETERM BIRTH BY MEASURING CELL FREE NUCLEIC ACIDS IN MATERNAL BLOOD - A nucleic acid normalization kit can include a nucleic acid having a normalization sequence including or complementary to one or more of SEQ ID NOs: 1-4 and 301-303 or unique segment thereof, the nucleic acid being present in an amount sufficient for use in a nucleic acid normalization protocol. The normalization kit can be used in a method of identifying a pregnancy normalization nucleic acid sequence. A nucleic acid diagnostic kit for diagnosing susceptibility to preterm birth (PTB) can include a nucleic acid having a CFP RNA PTB biomarker sequence including or complementary to one or more of SEQ ID NOs: 5-300 or unique segment thereof, the nucleic acid being present in an amount sufficient for use in a nucleic acid diagnostic protocol for diagnosing susceptibility to PTB. The diagnostic kit can be used in a method for predicting susceptibility of a pregnant woman to preterm birth (PTB). | 2013-11-07 |
20130296191 | Methods and Means for Molecular Classification of Colorectal Cancers - The invention relates to methods of typing a sample from a colorectal cancer patient based on the levels of RNA expression products in a cancer cell of the patient. The invention further relates to methods for determining a strategy for treatment of a patient suffering from colorectal cancer, and to methods for assigning treatment to a patient suffering from colorectal cancer. | 2013-11-07 |
20130296192 | Protein Arrays and Methods of Using and Making the Same - Methods and devices are provided for preparing a protein array having a plurality of proteins. In one embodiment, the method includes providing a plurality of nucleic acids each having a predefined sequence and expressing in vitro a plurality of proteins from the plurality of nucleic acids. In another embodiment, protein arrays having a solid surface and a microvolume are also provided. The solid surface can have a plurality of anchor oligonucleotides capable of hybridizing with a plurality of nucleic acids. The microvolume can cover each of the plurality of anchor oligonucleotides and can be configured to produce a polypeptide from each of the plurality of nucleic acids. | 2013-11-07 |
20130296193 | METHOD FOR DISCOVERING A BIOMARKER - The invention relates to a method for discovering biomarkers, comprising: matching the expression levels of genetic factors in persons, including a plurality of patients having a specific disease, for each of the persons; and comparing the expression levels of the genetic factors and genes corresponding thereto by any one or more of cluster analysis and correlation analysis to select some of the genetic factors. According to the invention, highly accurate biomarkers for a specific disease can be discovered in a simple and easy manner. | 2013-11-07 |
20130296194 | Methods and Devices for Nucleic Acid Synthesis - Methods and apparatus relate to the synthesis of polynucleotides having a predefined sequence on a support. Assembly methods include primer extension to generate overlapping construction oligonucleotides and assembly of the polynucleotides of interest onto an anchor support-bound oligonucleotides. Methods and apparatus for selection of polynucleotides having the predefined sequence and/or length are disclosed. | 2013-11-07 |
20130296195 | Selectively Functionalized Arrays - Methods, substrates, and devices related to arrays of optical confinements having surfaces with high levels of bias. Substrates having transparent or silica based portions and opaque or reflective portions are treated with 1) a selective passivating agent, that selectively coats the opaque or reflective regions, 2) a functionalizing agent such as a coupling agent, and 3) a selective removal agent, which selectively removes functionalizing agent from the passivated opaque or reflective surfaces. | 2013-11-07 |
20130296196 | METHODS, SYSTEMS AND DEVICES FOR MULTIPLE SINGLE-CELL CAPTURING AND PROCESSING USING MICROFLUIDICS - Methods, systems, and devices are described for multiple single-cell capturing and processing utilizing microfluidics. Tools and techniques are provided for capturing, partitioning, and/or manipulating individual cells from a larger population of cells along with generating genetic information and/or reactions related to each individual cell. Different capture configurations may be utilized to capture individual cells and then processing each individual cell in a multi-chamber reaction configuration. Some embodiments may provide for specific target amplification, whole genome amplification, whole transcriptome amplification, real-time PCR preparation, copy number variation, preamplification, mRNA sequencing, and/or haplotyping of the multiple individual cells that have been partitioned from the larger population of cells. Some embodiments may provide for other applications. Some embodiments may be configured for imaging the individual cells or associated reaction products as part of the processing. Reaction products may be harvested and/or further analyzed in some cases. | 2013-11-07 |
20130296197 | Device for Nucleic Acid Analysis and Nucleic Acid Analyzer - Sample nucleic acids are prevented from removing from a sample-immobilizing layer during a sequencing reaction. A reaction device for nucleic acid analysis is provided that enables high throughput analysis by increasing the number of nucleic acid samples that can be analyzed. The reaction device for nucleic acid analysis comprises a substrate, a sample-immobilizing layer on the substrate, nucleic acid samples or carriers having nucleic acid samples on their surfaces, which are immobilized on the sample-immobilizing layer, and a blocking layer that covers areas other than areas where the nucleic acid samples or the carriers are bound to the sample-immobilizing layer, wherein the immobilizing layer is formed of an inorganic oxide. | 2013-11-07 |
20130296198 | DIAGNOSTIC TESTS USING GENE EXPRESSION RATIOS - The invention provides methods for diagnosing biological states or conditions based on ratios of gene expression data from cell or tissue samples, such as cancer cell or tissue samples. The invention also provides sets of genes that are expressed differentially in normal and cancer lung cells and tissues. These sets of genes can be used to discriminate between normal and malignant cells or tissues, and between classes of malignant cells or tissues. Accordingly, diagnostic assays for classification of tumors, prediction of tumor outcome, selecting and monitoring treatment regimens and monitoring tumor progression/regression also are provided. | 2013-11-07 |
20130296199 | DRILLING LOST CIRCULATION MATERIAL - An engineered composition for reducing lost circulation in a well includes a mixture of coarse, medium and optional fine particles, and a blend of long fibers and short fibers. The long fibers are rigid and the short fibers are flexible. The long fibers form a tridimensional mat or net in the lost-circulation pathway that traps the mixture of particles and short flexible fibers to form a mud cake. The mixture of particles and blend of fibers may be added to water based and oil-based drilling fluids. The composition, size, and concentration of each component of the mixture of particles and blend of fibers may be fine-tuned for each application. | 2013-11-07 |
20130296200 | COMPOSITION BASED ON GEMINALS ZWITTERIONICS LIQUIDS AS WETTABILITY MODIFIERS IN ENHANCED OIL RECOVERY PROCESSES - The present invention relates to the application of geminals zwitterionics liquids based on bis-N-alkyl or bis-N-alkenyl or N-cycloalkyl or N-aryl bis-beta aminoacids or its salts thereof as wettability modifiers of rocks such as limestone, dolomite, sand, quartz or heterogeneous lithologies, in the presence of brines with high content of divalent ions such as calcium, magnesium, barium and strontium, high temperature and pressure in processes of enhanced oil recovery. Wettability modifier comprises a geminal zwitterionic liquid based on bis-N-alkyl or bis-N-alkenyl or N-cycloalkyl or N-aryl bis-beta aminoacids or its salts, using as solvent distilled or brine with a high content of divalent ions such as calcium and magnesium or organic solvents compounds derived from alcohols like methanol, ethanol, isopropanol or mixtures thereof, or aromatic as isomers of xylene, toluene, or diesel, gasoline or mixtures thereof. | 2013-11-07 |
20130296201 | METHOD AND COMPOSITION FOR ENHANCED HYDROCARBONS RECOVERY - An injectable fluid for treating a hydrocarbon containing formation is described. The injectable fluid includes ((i) when the salinity of the brine is from about 2 wt % to about 4 wt %, a composition that comprises a blend of a C | 2013-11-07 |
20130296202 | LUBRICATING OIL WITH IMPROVED WEAR PROPERTIES - Provided is a lubricating oil composition for internal combustion engines comprising at least one hydrocarbon base stock which is determined to exhibit a 100° C. PVC/40° C. PVC ratio approaching one or greater, and one or more lubricating additives. Also provided is a method for preparing such a composition, which includes determining the 100° C. PVC/40° C. PVC ratio of a hydrocarbon base stock oil, and selecting a hydrocarbon base stock oil which exhibits a 100° C. PVC/40° C. PVC ratio approaching one. One or more lubricating additives are then added to the selected base stock oil. | 2013-11-07 |
20130296203 | METHOD FOR IMPROVING THE FEATURES OF PHOSPHATE COATING - Properties of a phosphate coating are improved by preparing and applying a mixture containing nano-dimensioned hexagonal boron nitride, known as a solid lubricant, to a Zn, Zn-Ca, Fe and Mn phosphate coating. The hexagonal boron nitride is added to the coating bath during the phosphate treatment. Products coated with Zn, Zn-Ca, Fe and Mn phosphate accommodated with hexagonal boron nitride are disclosed. | 2013-11-07 |
20130296204 | SPHERICAL MOLYBDENUM DISULFIDE POWDERS, MOLYBDENUM DISULFIDE COATINGS, AND METHODS FOR PRODUCING SAME - Molybdenum disulfide powders include substantially spherically-shaped particles of molybdenum disulfide that are formed from agglomerations of generally flake-shaped sub-particles. The molybdenum disulfide powders are flowable and exhibit uniform densities. Methods for producing a molybdenum disulfide powder may include the steps of: Providing a supply of molybdenum disulfide precursor material; providing a supply of a liquid; providing a supply of a binder; combining the molybdenum disulfide precursor material with the liquid and the binder to form a slurry; feeding the slurry into a stream of hot gas; and recovering the molybdenum disulfide powder, the molybdenum disulfide powder including substantially spherically-shaped particles of molybdenum disulfide formed from agglomerations of generally flake-shaped sub-particles. | 2013-11-07 |
20130296205 | Straw Biolubricant - The present invention is related to a straw biolubricant, comprising 70-80% mineral oil, 6-11% straw biomass oil, and 15-20% active agent, wherein the active agent is sorbitol oleate. The straw biolubricant of the present invention comprises higher contact resistance and lower coefficient of friction in comparison with a conventional lubricant, and therefore to reduce the temperature of operating machine parts. | 2013-11-07 |
20130296206 | LUBRICANT THICKENED WITH OLEOPHILIC FIBERS - A lubricant comprises oleophilic thickening fibers dispersed in at least one of an oil and/or and a lubricating fluid. The oleophilic thickening fibers have a diameter between 50 nm and 10 microns and a length that is at least 5 times the diameter. | 2013-11-07 |
20130296207 | ADDITIVE FORMULATION SUITABLE FOR ANTISTATIC MODIFICATION AND IMPROVING THE ELECTRICAL CONDUCTIVITY OF INANIMATE ORGANIC MATERIAL - An additive formulation suitable for antistatic modification and improving the electrical conductivity of inanimate organic material, consisting essentially of | 2013-11-07 |
20130296208 | Lubricating Composition Containing An Antiwear Agent - The invention provides a lubricating composition containing an oil of lubricating viscosity and a compound obtained/obtainable by a process comprising reacting a glycolic acid, a 2-halo-acetic acid, or a lactic acid, or an alkali or alkaline metal salts thereof, (typically glycolic acid or a 2-halo-acetic acid) with at least one member selected from the group consisting of an amine, an alcohol, and an aminoalcohol. The invention further relates to the use of the lubricating composition in an internal combustion engine. | 2013-11-07 |
20130296209 | SYNTHESIS OF BIOLUBRICANT ESTERS FROM UNSATURATED FATTY ACID DERIVATIVES. - The present invention is generally directed to diester-based lubricant compositions comprising one or more isomeric mixtures of diester species. The present invention is also directed to methods of making these and other similar lubricant compositions. In some embodiments, the methods for making such diester-based lubricants utilize a biomass precursor material from which mono-unsaturated free lipid species can be provided or otherwise generated, wherein such mono-unsaturated free lipid species are converted to isomeric diol species en route to the synthesis of diester species for use as/in the diester-based lubricant compositions. | 2013-11-07 |
20130296210 | USE OF QUATERNIZED ALKYL AMINES AS ADDITIVE IN FUELS AND LUBRICANTS - The present invention relates to the use of quaternized alkylamine nitrogen compounds as a fuel additive and lubricant additive, such as, more particularly, as a detergent additive; for reduction or prevention of deposits in the injection systems of direct injection diesel engines, especially in common rail injection systems, for reduction of the fuel consumption of direct injection diesel engines, especially of diesel engines with common rail injection systems, and for minimization of power loss in direct injection diesel engines, especially in diesel engines with common rail injection systems; and as an additive for gasoline fuels, especially for operation of DISI engines. | 2013-11-07 |
20130296211 | BENEFIT AGENT CONTAINING DELIVERY PARTICLE - The present invention relates to benefit agent containing delivery particles, compositions comprising said particles, and processes for making and using the aforementioned particles and compositions. When employed in compositions, for example, cleaning or fabric care compositions, such particles increase the efficiency of benefit agent delivery, there by allowing reduced amounts of benefit agents to be employed. In addition to allowing the amount of benefit agent to be reduced, such particles allow a broad range of benefit agents to be employed. | 2013-11-07 |
20130296212 | SKIN CLEANSER COMPOSITION - The present invention relates to a skin cleanser composition capable of providing an excellent frictional resistance feeling during rinsing and capable of giving an excellent silky feeling with moisturization to the skin after drying, and to a method for producing the composition. The skin cleanser composition contains a cat ionized hydroxypropyl cellulose (A) and a surfactant (B), and the cationized hydroxypropyl cellulose (A) has an anhydroglucose-derived main chain, and has a degree of substitution with cationized ethyleneoxy group of from 0.01 to 3.0 and a degree of substitution with propyleneoxy group of from 0.01 to 2.9. | 2013-11-07 |
20130296213 | METHOD FOR CLEANING MEDICAL INSTRUMENT - The present invention discloses the method for cleaning a medical instrument using a treatment liquid, wherein the treatment liquid contains:
| 2013-11-07 |
20130296214 | AQUEOUS CLEANER FOR THE REMOVAL OF POST-ETCH RESIDUES - Cleaning compositions and processes for cleaning post-plasma etch residue from a microelectronic device having said residue thereon. The composition achieves highly efficacious cleaning of the residue material, including titanium-containing, copper-containing, tungsten-containing, and/or cobalt-containing post-etch residue from the microelectronic device while simultaneously not damaging the interlevel dielectric, metal interconnect material, and/or capping layers also present thereon. | 2013-11-07 |
20130296215 | WATER-RICH STRIPPING AND CLEANING FORMULATION AND METHOD FOR USING SAME - The present invention relates to water-rich formulations and the method using same, to remove bulk photoresists, post-etched and post-ashed residues, residues from Al back-end-of-the-line interconnect structures, as well as contaminations. The formulation comprises: hydroxylamine; corrosion inhibitor containing a mixture of alkyl dihydroxybenzene and hydroxyquinoline; an alkanolamine, a water-soluble solvent or the combination of the two; and at least 50% by weight of water. | 2013-11-07 |
20130296216 | COMPOSITION AND METHOD TO PROVIDE STAIN RELEASE AND STAIN REPELLENCY PROPERTIES TO SUBSTRATES - The present invention provides a composition for treatment, the composition comprising a fluorinated compound and a phosphate ester having at least one hydrocarbon residue having at least 6 carbon atoms. There is further provided a method of treatment applying the composition to a substrate. | 2013-11-07 |
20130296217 | OSCILLATOR CIRCUIT AND SYSTEM - The present invention is directed to a distributed dual-band oscillator suitable for low-phase-noise applications. The invention is configured to switch between the odd and even resonant modes of a fourth-order resonator. The switches used for mode selection do not conduct current and therefore do not affect the quality factor (Q) of the resonator. The benefit of this feature is relatively low phase noise. | 2013-11-07 |
20130296218 | NON-FLUOROPOLYMER SURFACE PROTECTION COMPOSITION - The present invention encompasses a surface treatment composition which comprises a polyorganosiloxane fluid-silicone resin mixture and a carrier. The polyorganosiloxane fluid-silicone resin mixture comprises about 50% to about 99.99% by weight of one or more polyorganosiloxane fluid compounds, at least 0.01% by weight of one or more silicone resin, and a maximum of 5% by weight of water. | 2013-11-07 |
20130296219 | Compositions Containing Secondary Paraffin Sulfonate And Alcohol Alkoxylate - The invention relates to compositions containing a) 45 to 65 wt. % of one or more secondary paraffin sulfonates with 8 to 22 carbon atoms, b) 1 to 10 wt. % of one or more alcohol alkoxylates which are produced from the reaction of alcohols R—OH, wherein R is an alkyl group with 9 to 11 carbon atoms, with alkoxylating agents selected from ethylene oxide, propylene oxide, or mixtures thereof and which contain on average 1 to 4 mol of structural units derived from the alkoxylating agents per 1 mol of structural units derived from the alcohols, and c) 25 to 52 wt. % water, in relation to the total weight of the composition in each case. The compositions can be used in an advantageous manner for producing washing and cleaning agents. | 2013-11-07 |
20130296220 | COMPOSITIONS COMPRISING QUAT COMPOUNDS AND ORGANOPOLYSILOXANES - Compositions useful as fabric softeners contain a long chain β-ketocarbonylquat containing at least one quaternary ammonium group and an organopolysiloxane polymer or siloxane copolymer. | 2013-11-07 |
20130296221 | IMPROVED CAPPING MODULES FOR DESIGNED ANKYRIN REPEAT PROTEINS - Improved N-terminal capping modules for designed ankyrin repeat proteins (DARPins) conferring improved thermal stability to the DARPins are described, as well as nucleic acids encoding such proteins, pharmaceutical compositions comprising such proteins and the use of such proteins in the treatment of diseases. | 2013-11-07 |
20130296222 | NOVEL BACTERIUM AND EXTRACTS OF SAID BACTERIUM AND THE USE OF SAME IN THERAPY - The present invention relates to a novel bacterial strain isolated and characterized from groundwater. The invention also relates to bacterial extracts and to the therapeutic use of same, notably in the context of the treatment of inflammations. | 2013-11-07 |
20130296223 | USE OF THYMOSIN ALPHA FOR THE TREATMENT OF SEPSIS - The present invention provides methods for preventing, treating, or reducing the severity of sepsis, severe sepsis or septic shock, including bacterial, viral, and fungal infections, and including infections of more complex etiology. The invention involves the administration of an alpha thymosin peptide regimen. In certain embodiments, the alpha thymosin peptide regimen is scheduled or timed with respect to potential, expected and/or diagnosed sepsis, severe sepsis or septic shock. In certain embodiments, the patient is immunodeficient or immunecompromised, and/or the patient is hospitalized or scheduled for hospitalization, such that the regimen of alpha thymosin peptide peptide helps to protect the patient from, or reduce the severity of, sepsis, severe sepsis or septic shock. | 2013-11-07 |
20130296224 | METHOD FOR TREATMENT OF INFLAMMATORY DISEASE AND DISORDER - The present disclosure provides a method, composition and kit for treatment of inflammatory disease and disorder using PKC isoform modulators. Exemplary modulators include inhibitors of PKC-alpha, PKC-epsilon and PKC-eta, as well as activators of PKC-delta. | 2013-11-07 |
20130296225 | Microcrystalline Y Receptor Agonists - The disclosure provides microcrystals of Y receptor agonists; microcrystalline pellets of Y receptor agonists, and microcrystalline suspensions of Y receptor agonists. Pharmaceutical compositions containing these microcrystals, microcrystalline pellets, and microcrystalline suspensions have prolonged pharmacokinetic profiles making them useful for once daily or once weekly administration. | 2013-11-07 |
20130296226 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS - Embodiments described herein are directed to methods for the treatment and control of hyperlipidemia, hypercholesterolemia, dyslipidemia, and other lipid disorders, and in delaying the onset of or reducing the risk of conditions and sequelae that are associated with these diseases, including atherosclerosis and non-insulin dependent diabetes. In addition, embodiments are directed to methods of treating coronary heart disease and metabolic syndrome. Embodiments are also directed to neurotensin analogs. In embodiments, the neurotensin analogs may be capable of binding to neurotensin receptors and, upon binding, may modulate the levels of lipids in subjects. | 2013-11-07 |
20130296227 | ANTIMICROBIAL CATIONIC PEPTIDES AND FORMULATIONS THEREOF - Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device. | 2013-11-07 |
20130296228 | EFFLUX PUMP INHIBITORS - Novel compositions and methods of reducing microbial resistance to antimicrobial agents and treating infections are disclosed. In particular, compositions and methods of inhibiting efflux pump activity, treating infection and methods of enhancing antimicrobial activity of antimicrobial agents are provided. | 2013-11-07 |
20130296229 | CASPOFUNGIN ANALOG AND APPLICATIONS THEREOF - Disclosed are a caspofungin analog and applications thereof. Said caspofungin analog is a compound having a structure as indicated in Formula (4), or pharmaceutically acceptable slats thereof. R1 can be chosen from hydroxyl, benzyloxy, phenoxy, substituted phenoxy, or substituted benzyloxy. R | 2013-11-07 |
20130296230 | METHOD FOR TREATING MALARIA, METHOD FOR KILLING MALARIA PARASITE, AND USE OF THE METHODS - A method of the present invention for treating malaria includes the step of administering, to a human or an animal, a therapeutically effective amount of drug for suppressing calcium ion exit from an intracellular organelle of the malaria parasite to an outside of the intracellular organelle and/or calcium ion entry from an outside of a cell of the malaria parasite into the cell. | 2013-11-07 |
20130296231 | CHARGED NUTRITIVE PROTEINS AND METHODS - Charged nutritive proteins are provided. In some embodiments the nutritive proteins an aqueous solubility of at least 12.5 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 50 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 100 g/L at pH 7. In some embodiments the nutritive proteins comprise at least one of a level of a) a ratio of branch chain amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of branch chain amino acid residues to total amino acid residues present in a benchmark protein; b) a ratio of leucine residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of leucine residues to total amino acid residues present in a benchmark protein; and c) a ratio of essential amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of essential amino acid residues to total amino acid residues present in a benchmark protein. Also provided are nucleic acids encoding the proteins, recombinant microorganisms that make the proteins, methods of making the proteins using recombinant microorganisms, compositions that comprise the proteins, and methods of using the proteins, among other things. | 2013-11-07 |
20130296232 | PEPTIDES CONTAINING TRYPTOPHAN - The present invention relates to a composition comprising a tryptophan-containing peptide and having a Trp/LNAA ratio of more than 0.1 for decreasing eating or appetite during or after stress. | 2013-11-07 |
20130296233 | Dietary Supplement and Methods of Use Thereof - The present disclosure provides a dietary supplement that includes plant ferritin; and methods of use of such a supplement. | 2013-11-07 |
20130296234 | LONG-TERM FEED-ELDERLY - The present invention provides methods of providing long-term and tube-fed nutrition to patients requiring same. More specifically, the present invention provides methods and compositions for providing long-term nutrition to an elderly patient. | 2013-11-07 |
20130296235 | CONTAINER AND METHOD FOR STORING A PHARMACEUTICAL AGENT - A container and method for storing a pharmaceutical agent are provided for enhancing the storage time. The storage time of the pharmaceutical agent is improved by reducing the loss of stabilizing agents in the pharmaceutical agent. The storage container is formed from a polyolefin that includes a stabilizing agent in an amount effective to reduce or inhibit the migration of stabilizing agents in the pharmaceutical agent. The polyolefin container is formed with a fatty acid amide such as erucamide for stabilizing insulin that contains m-cresol and/or phenol as stabilizing agents for the insulin. The fatty acid amide incorporated in the container inhibits and/or reduces the rate of migration of the m-cresol and/or phenol into the polyolefin to extend the storage life of the insulin. The container can be a syringe, such as a pre-filled syringe, a storage vial or the flow path of an infusion pump. | 2013-11-07 |
20130296236 | TREATMENT PROTOCOL OF DIABETES TYPE 2 - The present invention refers to a treatment protocol for diabetes type 2 patients. | 2013-11-07 |
20130296237 | Use Of Chloroquine To Treat Metabolic Syndrome - The present invention provides methods and compositions for modulating certain metabolic processes and for treating a variety of disorders associated with metabolic syndrome, including insulin related disorders, ischemia, oxidative stress, atherosclerosis, hypertension, obesity, abnormal lipid metabolism, and stroke by administering an effective dose of a chloroquine compound. The invention also provides methods and compositions relating to administering an effective dose of a chloroquine compound in combination with at least a second pharmaceutically active ingredient or compound including an antihyperglycemic diabetes treatment, an antihypertensive agent, an antithrombotic agent, and/or an inhibitor of cholesterol synthesis or absorption. | 2013-11-07 |
20130296238 | METHOD OF TREATING AMD IN PATIENTS REFRACTORY TO ANTI-VEGF THERAPY - Disclosed herein are methods for the treatment of a patient having an ocular conditions such as age-related macular degeneration or diabetic macular edema through administration of a recombinant binding protein comprising an ankyrin repeat domain. In some embodiments, the composition may be administered every 8 weeks to every 16 weeks. In some embodiments, the patient being treated may be refractory to existing anti-VEGF therapies. | 2013-11-07 |
20130296239 | Material for Wound Healing and Skin Reconstruction - The invention relates to a material for wound healing and skin reconstruction containing a peptide, wherein the peptide is a self-assembling peptide which is an amphiphilic peptide having 8 to 200 amino acid residues with periodic repeats of alternating hydrophilic amino acids and hydrophobic amino acids, and forms a stable β-sheet structure in an aqueous solution in the presence of a monovalent ion. The material for wound healing and skin reconstruction of the present invention is capable of healing a wound area of mammals quicker than spontaneous recovery without leaving any scars, wherein the material has no potential risk of infectious disease such as virus transmission. | 2013-11-07 |
20130296240 | PNEUMONIA BIOMARKERS - Ghrelin signal peptide fragment assays and kits useful in the diagnosis, prognosis, risk stratification, assessing, staging, monitoring, categorizing and determination of further diagnoses and treatment regimens in subjects with various disorders, diseases and conditions including, pneumonia, heart failure, or pneumonia and heart failure or suspected pneumonia, heart failure, or pneumonia and heart failure, and methods for monitoring treatment. | 2013-11-07 |
20130296241 | AQUARETIC AND NATRIURETIC POLYPEPTIDES LACKING VASODILATORY ACTIVITY - This document provides aquaretic and natriuretic polypeptides. For example, this document provides polypeptides having aquaretic and/or natriuretic activities. In some cases, a polypeptide provided herein can have aquaretic and natriuretic activities, while lacking the ability to lower blood pressure. This document also provides methods and materials for inducing aquaretic and/or natriuretic activities within a mammal. | 2013-11-07 |
20130296242 | MEDICATION AND THERAPY TREATING OF CHOROIDAL NEOVASCULARIZATION - A medication for treating choroidal neovascularization comprises an amino acid fragment that derives from an angiogenesis inhibiting factor and comprises amino acid sequences as set forth in SEQ ID NO: 1. Moreover, a therapy of treating choroidal neovascularization by administering the said medication to an individual, with the medication comprising 0.1-1000 μg of the amino acid fragment in 1 ml solvent. | 2013-11-07 |
20130296243 | MODIFIED RECOMBINANT FACTOR VIII AND VON WILLEBRAND FACTOR AND METHODS OF USE - The present invention provides novel methods of increasing the survival of a coagulation protein by inhibiting the interaction with a clearance receptor. The invention also provides methods of preparing compositions that inhibit coagulation protein clearance receptors. Conjugated coagulation proteins, including compositions and formulations thereof, are also provided by the present invention. | 2013-11-07 |
20130296244 | VARIANT OF ANTIHEMOPHILIC FACTOR VIII HAVING INCREASED SPECIFIC ACTIVITY - The present invention is in the field of hemophilia therapy. It relates to a new variant of antihemophilic factor VIII having increased specific activity in comparison to known factor VIII products. | 2013-11-07 |
20130296245 | PROLINAMIADE DERIVATIVES AS THROMBIN INHIBITOR, PREPRARATION METHOD AND APPLICATION THEREOF - Provided are a compound of formula (I), pharmaceutically acceptable salts thereof, preparation methods and applications thereof for inhibiting thrombin, and applications in the treatment and prevention of thrombin-mediated and thrombin-related diseases. | 2013-11-07 |
20130296246 | COMPOSITION - The invention relates to a composition comprising albumin and a therapeutic agent, particularly a gene therapy vector. The composition is useful in the treatment of glioma. | 2013-11-07 |
20130296247 | Analogs of Sodium Channel Peptide Toxin - The present invention relates to a peptide and analogs thereof that selectively inhibit the Na | 2013-11-07 |
20130296248 | Methods of Treating Depression and Other Related Diseases - The invention relates to methods for treating depression, anxiety, and other related diseases by administering a peptide NMDAR partial agonist. | 2013-11-07 |
20130296249 | METHODS OF BLOCKING TISSUE DESTRUCTION BY AUTOREACTIVE T CELLS - Methods for blocking autoreactive T cell-initiated destruction of tissues in a mammal are provided. In one embodiment, the method comprises administering a purified CD24 polypeptide, a fusion protein comprising such polypeptide, or a biologically active fragment of such polypeptide to a mammalian subject who is suspected of having or predisposed to having an autoimmune disease. In another embodiment, anti-CD24 antibody or anti-CD24 Fab fragments are administered to the subject. In another embodiment, the method comprises administering a CD24 antisense molecule, an expression vector encoding a CD24 antisense molecule, CD24 dsRNAi, or an expression vector encoding CD24 dsRNAi to the subject. The present invention also relates to isolated and purified CD24 fusion proteins employed in the present methods and to transgenic mice that express the human CD24 protein on their T cells and/or their vascular endothelial cells but do not express murine heat shock antigen on any cells. | 2013-11-07 |
20130296250 | METHOD FOR TREATMENT OF PSORIASIS - The present disclosure provides a method and kit for treatment of psoriasis using PKC-alpha inhibitors. Exemplary inhibitors include peptide PKC-alpha inhibitors which specifically inhibit PKC-alpha activity leading to the attenuation and treatment of psoriasis. | 2013-11-07 |
20130296251 | COSMETIC AND/OR PHARMACEUTICAL COMPOSITION COMPRISING A YEAST PEPTIDE HYDROLYSATE AND USE OF THE YEAST PEPTIDE HYDROLYSATE AS AN ACTIVE AGENT FOR STRENGTHENING HAIR - A method of attenuating or preventing hair loss in a human in need thereof comprising applying to the human in need thereof a composition comprising an effective amount of a hair-loss attenuating peptide hydrolysate and a cosmetically acceptable carrier. | 2013-11-07 |
20130296252 | MUC18 TARGETING PEPTIDES - Provided are MUC18 targeting peptides which may be used, e.g., to therapeutically target B-1 lymphocytes to reduce the influence of these cells on the metastatic potential of melanoma cells and/or to target cancerous cells, including certain melanoma and leukemia cells. MUC18 targeting peptides may be comprised in fusion constructs, imaging constructs, and/or therapeutic constructs such as fusion constructs which may be used for diagnosing or treating a cancer. | 2013-11-07 |
20130296253 | Uses of an Immunomodulatory Protein (GMI) from Ganoderma Microsporum - The invention provides a method for inhibiting EGF receptor activity comprising contacting an | 2013-11-07 |
20130296254 | COMPSTATIN AND ANALOGS THEREOF FOR EYE DISORDERS - The present invention features the use of compstatin and complement inhibiting analogs thereof for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, choroidal neovascularization, and/or retinal neovascularization. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a second therapeutic agent. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a gel-forming material, e.g., soluble collagen, and methods of administering the compositions. | 2013-11-07 |
20130296255 | Methods and Reagents for Treatment of Age-Related Macular Degeneration - The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD. | 2013-11-07 |
20130296256 | Melanocortin-1 Receptor-Specific Cyclic Peptides - Melanocortin receptor-specific cyclic peptides of the formula | 2013-11-07 |
20130296257 | COBALAMIN ACQUISITION PROTEIN AND USE THEREOF - The present invention relates to a cobalamin acquisition protein, compositions containing the cobalamin acquisition protein, and the use of such compositions. | 2013-11-07 |
20130296258 | MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC-3) - Described are specific-binding therapeutic and/or diagnostic proteins directed against Glypican-3 (GPC3), which proteins include muteins of a lipocalin protein, such as lipocalin 2 (Lcn2 or NGAL). The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins. | 2013-11-07 |
20130296259 | PHARMACEUTICAL COMPOSITIONS CONTAINING BOTULINUM NEUROTOXIN - This invention relates to the use of a composition comprising a polysaccharide and a botulinum toxin for reducing a skin wrinkle. In some embodiments, the polysaccharide comprises disaccharides. In some embodiments, the average molecular weight of a disaccharide unit of the polysaccharide is between about 345 D and about 1,000 D. | 2013-11-07 |
20130296260 | METHOD FOR PREVENTION OR TREATMENT OF INTRACTABLE INFLAMMATORY BOWEL DISEASE - An object of the present invention is to provide methods for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease. The object can be achieved by a method for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease in a patient in need of the prevention or treatment of the inflammatory bowel disease, comprises administering an effective amount of adrenomedullin, a modified product thereof having an activity of suppressing steroid-resistant or steroid-dependent inflammation, or a salt thereof having an activity of suppressing steroid-resistant or steroid-dependent inflammation, to the patient. | 2013-11-07 |
20130296261 | Cancer Treatment Method - The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines and at least one additional anti-neoplastic compound. In particular, the method relates to a methods of treating cancers by administration of N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof in combination with at least one additional anti-neoplastic compound. | 2013-11-07 |
20130296262 | HYALURONIC ACID STABILIZER - An embodiment of the present disclosure provides a composition that comprises hyaluronic acid, or its salt or derivative thereof, and an antimicrobial agent, such as zinc citrate, that does not degrade the hyaluronic acid molecule. | 2013-11-07 |
20130296263 | HYALURONIC ACID STABILIZER - An embodiment of the present disclosure provides a composition that includes hyaluronic acid, or its salt or derivative thereof, zinc citrate and an additive selected from the group consisting of grapefruit seed extract, Citricidal™, calcium propionate, sodium benzoate, potassium benzoate, magnesium citrate, proline, raddish root extract, Leucidal™ or 1,2-propanediol. | 2013-11-07 |
20130296264 | OPHTHALMIC COMPOSITIONS WITH IMPROVED DESSICATION PROTECTION AND RETENTION - The present invention relates to artificial tear compositions and ophthalmic compositions suitable for drug delivery. In one embodiment of the present invention, the compositions comprise a galactomannan polymer such as guar or hydroxypropyl guar, hyaluronic acid, and a cis-diol such as sorbitol. In a preferred embodiment, the compositions also comprise a borate compound. | 2013-11-07 |
20130296265 | Methods of Skin Treatment and Use of Water-Soluble Beta-(1,3) Glucans as Active Agents for Producing Therapeutic Skin Treatment Agents - A method of treating an ulcer comprising applying to the ulcer a preparation comprising a water-soluble β-(1,3) glucan with β-(1,6) linked side-chains, where the side-chains comprise β-(1,3) linkages or up to four consecutive β-(1,6) linkages a active ingredients. | 2013-11-07 |
20130296266 | Pharmaceutical Composition of Complex Carbohydrates and Essential Oils and Methods of Using the Same - The invention discloses the discovery that a pharmaceutical composition containing complex carbohydrates with or without natural or synthetic essential oils can work effectively as a topical, oral or mucosal pharmaceutical composition. Such pharmaceutical compositions reduce inflammation, assist in wound healing, protect against bruising, relieve itching, relieve pain and swelling and treat topical bacterial infections such as acne and decubitus ulcers and prevent and treat numerous other conditions and diseases. Such pharmaceutical compositions can be administered to mammals including humans. Also included in this invention are methods to deliver topically applied macromolecules into the tissue of mammals and methods of blocking the adhesion, metastatic and coronary cascades. | 2013-11-07 |
20130296267 | AGENT FOR INTRA-ARTICULAR INJECTION - The present invention relates to agents for intra-articular injection that contain a mixture of alpha-tocopherol, phospholipids or poloxamers or sodium oleate, proteoglycans, and a cortisone crystal suspension or a cortisone crystal solution. The agents are suitable for therapy of rheumatic diseases, in particular of arthrosis. | 2013-11-07 |
20130296268 | PHARMACEUTICAL COMPOSITION CONTAINING DOCETAXEL-CYCLODEXTRIN INCLUSION COMPLEX AND ITS PREPARING PROCESS - A docetaxel inclusion complex having improved water-solubility (up to 15 mg/ml) and stability (stability constant Ka=2056 M | 2013-11-07 |
20130296269 | 5-Halogenopyrazolecarboxamides - The present invention relates to novel 5-halogenopyrazole(thio)carboxamides, their process of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions. | 2013-11-07 |
20130296270 | METHOD FOR INHIBITING MICROORGANISMS OR PLANT PESTS USING EXFOLIATED CLAY/SURFACTANT COMPLEX - The present invention provides a method for inhibiting microorganisms or plant pests using exfoliated clay/surfactant complex. The weight ratio of the exfoliated clay to the surfactant can range from 99/1 to 1/99. Preferably, the exfoliated clay is an inorganic layered clay on a nano scale and the surfactant is cationic, nonionic, anionic or amphoteric. | 2013-11-07 |
20130296271 | Agri-Horticultural Pest Control Compositions Comprising 4-(3-Butynyl)Aminopyrimidine Derivatives - Agri-horticultural pest control compositions having outstanding control effect on pests, in particular, agri-horticultural pests, which comprise as active ingredients one or more 4-(3-butynyl)aminopyrimidine derivatives represented by the general formula [I], namely, | 2013-11-07 |
20130296272 | HETEROARYLPIPERIDINE AND -PIPERAZINE DERIVATIVES AS FUNGICIDES - Heteroarylpiperidine and -piperazine derivatives of the formula (I) | 2013-11-07 |
20130296273 | TREATMENT OF BLOOD CANCER - Hypoxia activated prodrugs, such as, e.g., TH-281, TH-302, and TH-308, are useful for the treatment of various blood cancers, such as acute leukemias, chronic leukemias, MDS, MF, and multiple myeloma. | 2013-11-07 |
20130296274 | PYRROLIDINONES AS METAP-2 INHIBITORS - Compounds of the formula I in which R | 2013-11-07 |
20130296275 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS - The present invention relates to compounds of the Formula (I) that are useful antimicrobial agents and effective against a variety of multi-drug resistant bacteria: | 2013-11-07 |
20130296276 | HETEROCYCLIC RING COMPOUND - The present invention provides a compound having a muscle cell or adipocyte differentiation regulating action, useful for the prophylaxis or treatment of diseases such as diabetes, obesity, dyslipidemia and the like, and the like, and having superior efficacy. | 2013-11-07 |
20130296277 | Pharmaceutical Compositions for the Treatment of Parasitic Diseases, Cancer, or Skin Diseases by Topical Administration - The present invention relates to pharmaceutical compositions for the treatment of parasitic diseases, cancer, or skin diseases by topical administration and especially ointments for the treatment of leishmaniasis. The present invention further relates to the use of the present ointments for the treatment of parasitic diseases, cancer, or skin diseases and especially ointments for the treatment of leishmaniasis in both humans and animals. Specifically, the present invention relates to pharmaceutical compositions such as ointments and crèmes for the treatment of parasitic diseases, cancer, or skin diseases by topical administration comprising 0.1 to 20 weight %, preferably 0.1 to 10 weight %, more preferably 0.1 to 7 weight %, most preferably 0.5 to 5 weight %, of the pharmaceutical composition oleyl phosphocholine as an active ingredient. | 2013-11-07 |
20130296278 | Diazeniumdiolate Derivatives - A compound having the structure (I) useful for treating hypertension, pulmonary arterial hypertension, congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy. | 2013-11-07 |